Tarveda Therapeutics to Present Data from Phase 1 Study of PEN-221 at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

WATERTOWN, Mass.–(BUSINESS WIRE)–Tarveda
Therapeutics, Inc.
, a clinical stage biopharmaceutical company
discovering and developing Pentarins™ as a new class of potent and
selective cancer medicines, today announced that it will present Phase 1
results from a Phase 1/2a study of PEN-221 in patients with
neuroendocrine tumors or small cell lung cancer at the 2018 American
Society for Clinical Oncology (ASCO) Annual Meeting occurring June 1-5,
2018 in Chicago IL.

The data presented will describe the safety, tolerability,
pharmacokinetics, and preliminary efficacy of PEN-221, a miniature drug
conjugate containing a peptide ligand that is highly selective in
targeting the somatostatin receptor 2 (SSTR2) that is conjugated to the
potent payload DM1. SSTR2 is a cell surface target that is overexpressed
in a variety of solid tumor cancers. PEN-221 is currently being
evaluated in a Phase 2a trial in patients with gastrointestinal midgut
neuroendocrine tumors, pancreatic neuroendocrine tumors, or small cell
lung cancer.

We are very pleased to have completed the Phase 1 portion of our Phase
1/2a clinical trial for PEN-221 on schedule and to present the data from
the Phase 1 trial evaluating PEN-221 at ASCO,” said Drew Fromkin,
President and Chief Executive Officer of Tarveda. “We are encouraged by
the data from studies of PEN-221 to date and look forward to advancing
the Phase 2a portion of the study for PEN-221 as well as our Phase 1
trial for PEN-866.”

Details of the poster presentation are as follows:

Title: First
in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1
conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or
small cell lung cancer (SCLC): Phase 1 results.

Abstract
Number: 4097
Date: June 3, 2018
Time: 8:00 – 11:30 AM CT
Location:
Hall A

About Pentarins™

Tarveda is developing Pentarins™, potent and selective miniature drug
conjugates with high affinity for specific cell surface and
intracellular targets. Pentarins are engineered to bind to their tumor
cell targets and provide sustained release of their potent therapeutic
payloads deep into solid tumor tissue. Comprised of a targeting ligand
conjugated to a potent cancer cell killing agent through a tuned
chemical linker, Pentarins are designed to overcome the deficits of both
larger antibody drug conjugates and small molecules that limit their
therapeutic effectiveness against solid tumors. Together, the components
of Tarveda’s Pentarins have distinct, yet synergistic, anticancer
attributes: the small size of Pentarins allows for rapid and deep
penetration into the tumor tissue, the ligand’s targeting ability allows
for specific binding and retention in tumor cells, and the chemical
linker is tuned to optimize the release of the potent, cell killing
payload inside the cancer cells for efficacy.

About Tarveda Therapeutics, Inc.

Tarveda Therapeutics, Inc. discovers and develops Pentarins™, a new
class of potent and selective miniature drug conjugates with enhanced
targeting capabilities for the treatment of a wide range of solid tumor
cancers. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniature
drug conjugate that targets the somatostatin receptor 2 (SSTR2) for
treatment of patients with neuroendocrine, small cell lung, prostate,
and other cancers that express SSTR2. PEN-221 comprises a highly
selective peptide for SSTR2 conjugated to the potent cytotoxic payload,
DM1, through a tuned cleavable linker. Tarveda is also advancing its
Pentarin HSP90 drug conjugate platform with lead drug candidate PEN-866,
which is a miniature drug conjugate that selectively binds to the
intracellular target, Heat Shock Protein 90 (HSP90), and is linked to
the payload SN-38, the highly potent active metabolite of irinotecan.
Tarveda’s strategy includes developing its own proprietary Pentarins as
well as applying the Pentarin platform to enhance the effectiveness of
the targeting moieties and novel payloads of pharmaceutical
collaborators. www.tarveda.com

Contacts

MacDougall Biomedical Communications
George E. MacDougall,
781-235-3060
george@macbiocom.com